开发了一种有效的合成先前无法获得的2-取代的二氟环丁烷结构单元的方法,并已应用于多克规模。合成序列的关键步骤包括O保护的2-(羟甲基)环丁酮的脱氧氟化作用。测量了2,2-二氟环丁烷胺和2,2-二氟环丁烷羧酸或其衍生物的解离常数(p K a)和log P值,并将其与相应的3,3-二氟环丁烷衍生物和非氟化对应物所获得的值进行比较。使用X射线晶体学数据的出口向量图分析比较了2,2-和3,3-二氟环丁胺的三维结构。
[EN] HETEROCYCLIC GLP-1 AGONISTS<br/>[FR] AGONISTES HÉTÉROCYCLIQUES DE GLP-1
申请人:GASHERBRUM BIO INC
公开号:WO2022028572A1
公开(公告)日:2022-02-10
This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase enzymes. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase enzymes. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.